-
Something wrong with this record ?
Effects of cannabidiol on psychosocial stress, situational anxiety and nausea in a virtual reality environment: a protocol for a single-centre randomised clinical trial
Z. Bawa, D. McCartney, M. Bedoya-Pérez, NS. Lau, R. Fox, H. MacDougall, IS. McGregor
Language English Country England, Great Britain
Document type Clinical Trial Protocol, Journal Article
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Nursing & Allied Health Database (ProQuest)
from 2011-01-01
Health & Medicine (ProQuest)
from 2011-01-01
Family Health Database (ProQuest)
from 2011-01-01
Psychology Database (ProQuest)
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
- MeSH
- Double-Blind Method MeSH
- Cannabidiol * therapeutic use MeSH
- Motion Sickness * drug therapy MeSH
- Humans MeSH
- Nausea drug therapy MeSH
- Stress, Psychological MeSH
- Randomized Controlled Trials as Topic MeSH
- Anxiety drug therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial Protocol MeSH
- Geographicals
- Australia MeSH
INTRODUCTION: The non-intoxicating plant-derived cannabinoid, cannabidiol (CBD), has demonstrated therapeutic potential in a number of clinical conditions. Most successful clinical trials have used relatively high (≥300 mg) oral doses of CBD. Relatively few studies have investigated the efficacy of lower (<300 mg) oral doses, typical of those available in over-the-counter CBD products. METHODS: We present a protocol for a randomised, double-blind, placebo-controlled, parallel-group clinical trial investigating the effects of a low oral dose (150 mg) of CBD on acute psychosocial stress, situational anxiety, motion sickness and cybersickness in healthy individuals. Participants (n=74) will receive 150 mg of CBD or a matched placebo 90 min before completing three virtual reality (VR) challenges (tasks) designed to induce transient stress and motion sickness: (a) a 15 min 'Public Speaking' task; (b) a 5 min 'Walk the Plank' task (above a sheer drop); and (c) a 5 min 'Rollercoaster Ride' task. The primary outcomes will be self-reported stress and nausea measured on 100 mm Visual Analogue Scales. Secondary outcomes will include salivary cortisol concentrations, skin conductance, heart rate and vomiting episodes (if any). Statistical analyses will test the hypothesis that CBD reduces nausea and attenuates subjective, endocrine and physiological responses to stress compared with placebo. This study will indicate whether low-dose oral CBD has positive effects in reducing acute psychosocial stress, situational anxiety, motion sickness and cybersickness. ETHICS AND DISSEMINATION: The University of Sydney Human Research Ethics Committee has granted approval (2023/307, version 1.6, 16 February 2024). Study findings will be disseminated in a peer-reviewed journal and at academic conferences. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12623000872639).
RPA Institute of Academic Surgery Sydney Local Health District Sydney New South Wales Australia
School of Psychology The University of Sydney Sydney New South Wales Australia
Sydney Pharmacy School The University of Sydney Sydney New South Wales Australia
The Brain and Mind Centre The University of Sydney Sydney New South Wales Australia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006662
- 003
- CZ-PrNML
- 005
- 20240423155431.0
- 007
- ta
- 008
- 240412s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/bmjopen-2023-082927 $2 doi
- 035 __
- $a (PubMed)38531572
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bawa, Zeeta $u The Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia $u The Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia $u Sydney Pharmacy School, The University of Sydney, Sydney, New South Wales, Australia $1 https://orcid.org/0000000223467557
- 245 10
- $a Effects of cannabidiol on psychosocial stress, situational anxiety and nausea in a virtual reality environment: a protocol for a single-centre randomised clinical trial / $c Z. Bawa, D. McCartney, M. Bedoya-Pérez, NS. Lau, R. Fox, H. MacDougall, IS. McGregor
- 520 9_
- $a INTRODUCTION: The non-intoxicating plant-derived cannabinoid, cannabidiol (CBD), has demonstrated therapeutic potential in a number of clinical conditions. Most successful clinical trials have used relatively high (≥300 mg) oral doses of CBD. Relatively few studies have investigated the efficacy of lower (<300 mg) oral doses, typical of those available in over-the-counter CBD products. METHODS: We present a protocol for a randomised, double-blind, placebo-controlled, parallel-group clinical trial investigating the effects of a low oral dose (150 mg) of CBD on acute psychosocial stress, situational anxiety, motion sickness and cybersickness in healthy individuals. Participants (n=74) will receive 150 mg of CBD or a matched placebo 90 min before completing three virtual reality (VR) challenges (tasks) designed to induce transient stress and motion sickness: (a) a 15 min 'Public Speaking' task; (b) a 5 min 'Walk the Plank' task (above a sheer drop); and (c) a 5 min 'Rollercoaster Ride' task. The primary outcomes will be self-reported stress and nausea measured on 100 mm Visual Analogue Scales. Secondary outcomes will include salivary cortisol concentrations, skin conductance, heart rate and vomiting episodes (if any). Statistical analyses will test the hypothesis that CBD reduces nausea and attenuates subjective, endocrine and physiological responses to stress compared with placebo. This study will indicate whether low-dose oral CBD has positive effects in reducing acute psychosocial stress, situational anxiety, motion sickness and cybersickness. ETHICS AND DISSEMINATION: The University of Sydney Human Research Ethics Committee has granted approval (2023/307, version 1.6, 16 February 2024). Study findings will be disseminated in a peer-reviewed journal and at academic conferences. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12623000872639).
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a kanabidiol $x terapeutické užití $7 D002185
- 650 _2
- $a úzkost $x farmakoterapie $7 D001007
- 650 _2
- $a nauzea $x farmakoterapie $7 D009325
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 12
- $a kinetózy $x farmakoterapie $7 D009041
- 650 _2
- $a psychický stres $7 D013315
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 651 _2
- $a Austrálie $7 D001315
- 655 _2
- $a protokol klinické studie $7 D000078325
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a McCartney, Danielle $u The Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia $u The Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia $u School of Psychology, The University of Sydney, Sydney, New South Wales, Australia
- 700 1_
- $a Bedoya-Pérez, Miguel $u The Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia $u The Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia $u School of Psychology, The University of Sydney, Sydney, New South Wales, Australia
- 700 1_
- $a Lau, Namson S $u The Boden Initiative, Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia
- 700 1_
- $a Fox, Richard $u Yellow Dog Man Studios s.r.o, Ostrava-jih-Zábřeh, Czechia
- 700 1_
- $a MacDougall, Hamish $u RPA Institute of Academic Surgery, Sydney Local Health District, Sydney, New South Wales, Australia
- 700 1_
- $a McGregor, Iain S $u The Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia iain.mcgregor@sydney.edu.au $u The Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia $u School of Psychology, The University of Sydney, Sydney, New South Wales, Australia $1 https://orcid.org/0000000293077159
- 773 0_
- $w MED00184484 $t BMJ open $x 2044-6055 $g Roč. 14, č. 3 (2024), s. e082927
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38531572 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155428 $b ABA008
- 999 __
- $a ok $b bmc $g 2080963 $s 1216429
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 14 $c 3 $d e082927 $e 20240325 $i 2044-6055 $m BMJ open $n BMJ Open $x MED00184484
- LZP __
- $a Pubmed-20240412